Epithalon (also spelled Epitalon) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — derived from Epithalamin, a polypeptide extract of the pineal gland. Developed by Professor Vladimir Khavinson of the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon has been studied for over 35 years with a focus on longevity, telomere biology, pineal function, and age-related disease prevention. It has one of the more substantial research histories of any longevity-focused peptide.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Epithalon is primarily researched for longevity and anti-aging applications. Its mechanisms include telomerase activation (telomere extension), pineal gland restoration and melatonin normalisation, antioxidant effects, and immune modulation. Research by Khavinson's group has shown extended lifespan in animal models and improved aging biomarkers in elderly human subjects.
How Does Epithalon Work?
Epithalon's most discussed mechanism involves telomere biology. Telomeres are the protective caps on chromosomes that shorten with each cell division — their progressive shortening is a central mechanism of cellular aging. Epithalon has been shown in multiple studies to activate telomerase, the enzyme that can rebuild and extend telomeres, in somatic cells that don't normally express it. This telomere extension capacity has made Epithalon one of the most studied peptides in the longevity research space.
The second major mechanism involves the pineal gland. The pineal gland regulates circadian rhythms and melatonin production, and its function declines significantly with age — contributing to disrupted sleep, reduced antioxidant capacity, and dysregulated immune function. Khavinson's research showed that Epithalon can restore pineal secretory function in aged animals, normalising melatonin production and improving circadian regulation.
Additional mechanisms include antioxidant effects (Epithalon reduces lipid peroxidation and 8-hydroxy-2-deoxyguanosine, a DNA oxidation marker), immunomodulatory activity, and retinal protection in models of retinal degeneration.
Khavinson's Research and the Human Data
Professor Khavinson's group has published extensively on Epithalon across cell culture, animal, and human studies — an unusually comprehensive evidence base for a peptide in this space. Key findings:
In human clinical studies of elderly patients, Epithalon improved a range of biomarkers of aging: reduced cardiovascular disease incidence, improved immune parameters, normalised cortisol and melatonin rhythms, and showed antitumour effects in some cancer endpoints. Notably, a long-term (12-year) prospective study of elderly patients treated with thymic and pineal peptides including Epithalon showed significantly reduced mortality compared to untreated controls.
Animal lifespan studies in mice and Drosophila showed extended maximum lifespan with Epithalon treatment — one of the very few longevity interventions to show this in mammals. The mechanism appears to involve both telomere extension and reduced oxidative damage.
The telomere extension findings have been replicated in cultured human cells and have driven significant interest from the longevity research community, though the in vivo significance in humans at typical research doses remains an active question.
Dosing and Cycling Protocols
| Protocol | Dose | Route | Duration | Frequency |
|---|---|---|---|---|
| Khavinson protocol | 5–10 mg/day | SubQ or IM | 10 days | 1–2 cycles/year |
| Community maintenance | 2–5 mg/day | SubQ | 10–20 days | Quarterly |
| Sleep/circadian focus | 5 mg | SubQ before sleep | 10–14 days | 2x/year |
| Extended cycle | 3 mg/day | SubQ | 30 days | Twice yearly |
Safety Profile and Considerations
Epithalon has been studied in humans over decades and has an excellent safety profile in published research. No serious adverse events have been attributed to Epithalon in Khavinson's clinical research or in the broader community research experience.
**Cycling is standard:** Epithalon is used in defined cycles rather than daily indefinitely. The 10-day cycle pattern from Khavinson's research is the most common community protocol. The rationale is precautionary rather than evidence-based — telomerase activation has theoretical cancer implications that long-term continuous use might exaggerate.
**Cancer concern:** Telomerase is active in most cancer cells, which is how tumours achieve replicative immortality. The theoretical concern that telomerase activation by Epithalon could accelerate existing tumours is real and worth noting. No evidence from Khavinson's research or community use has documented this outcome, and some of his work showed antitumour effects. Nonetheless, use in individuals with known malignancy or high cancer risk requires careful consideration.
**Interactions with melatonin:** Since Epithalon restores pineal function and melatonin production, exogenous melatonin supplementation may be unnecessary or redundant during an Epithalon cycle.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Epithalon is primarily researched for longevity and anti-aging applications. Its mechanisms include telomerase activation (telomere extension), pineal gland restoration and melatonin normalisation, antioxidant effects, and immune modulation. Research by Khavinson's group has shown extended lifespan in animal models and improved aging biomarkers in elderly human subjects.
Yes — Epithalon has been shown to activate telomerase and extend telomeres in cultured human cells. Whether this produces meaningful telomere lengthening in vivo in adult humans at typical research doses is less certain but biologically plausible. It remains one of the few peptides with documented telomerase-activating activity.
Sleep quality improvements from pineal restoration are often noticed within the 10-day cycle. Longer-term effects on aging biomarkers require consistent use over months to years. Because Epithalon's primary value is in slowing age-related decline rather than acute therapeutic effects, the timeline for meaningful benefit is measured in longer cycles and sustained use over years.
Epithalon has been used in human research for over 35 years by Khavinson's group with an excellent safety record. No serious adverse events have been documented. The theoretical concern around telomerase activation and cancer risk is noted but has not been observed in available research. Standard precaution is to cycle rather than use continuously and avoid use in individuals with active malignancy.
Melatonin is a direct circadian signal — you're adding the hormone. Epithalon restores the pineal gland's ability to produce its own melatonin — it works upstream, addressing the source of age-related melatonin decline rather than supplementing around it. Epithalon also has telomerase activation, antioxidant, and immunomodulatory effects that melatonin does not.
Khavinson's protocols often combined pineal peptides (like Epithalon) with thymic peptides (like Thymalin) for synergistic immune and endocrine effects. Community protocols commonly stack Epithalon with GHK-Cu and BPC-157. The combinations are generally considered safe given the different mechanisms involved.